ArticleChinese journal of integrative medicine2026
Zhangyanming Tablets for Dry Eye Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of Zhangyanming Tablets (ZYMT) combined with 0.1% sodium hyaluronate eye drops for dry eye disease (DED).
methodsA stratified, randomized, doubleblind, placebo-controlled multicenter trial was conducted from June 2022 to August 2024, enrolling 144 patients with DED from 3 centers. Participants were randomized 1:1 to either the ZYMT group (ZYMT + 0.1% sodium hyaluronate, n=72) or the control group (placebo + 0.1% sodium hyaluronate, n=72). Participants received the study tablets (2 tablets orally, 3 times daily) concurrently with the eye drops (1 drop, 5 times daily) for 8 weeks. The primary outcome was the mean change from baseline in the ocular surface disease index (OSDI) score. The secondary outcomes included the efficacy rate, the mean change from baseline in the tear film breakup time (TFBUT), Schirmer's test, corneal fluorescein staining (CFS) and Chinese medicine (CM) syndrome score. Safety was assessed by monitoring adverse events, vital signs, and laboratory parameters (hematology, urinalysis, liver and kidney functions, and electrocardiogram).
resultsA total of 119 patients completed this study, among which 58 were in the ZYMT group and 61 were in the control group. After 8 weeks of treatment, the mean change from baseline in the OSDI score in the ZYMT group was significantly greater than those in the control group in week 8 [absolute difference -5.66, 95% confidence interval (CI), -9.56 to -1.76]. The efficacy rate was 62.1% (36/58) in the ZYMT group versus 42.6% (26/61) in the control group (relative risk: 1.46, 95% CI, 1.02 to 2.08). The mean changes from baseline in TFBUT and CM symptom score were significantly greater in the ZYMT group than those in the control group at week 8 (P<0.05). No significant differences were observed between the two groups in Schirmer's test, CFS, or safety data (all P>0.05).
conclusionZYMT combined with 0.1% sodium hyaluronate eye drops can significantly alleviate the ocular symptoms, improve tear film, and demonstrate a good safety. (Registration No. ChiCTR2200061479).
Indexed as
Identifiers
42730904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.